270 related articles for article (PubMed ID: 10064571)
1. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Dehal SS; Brodie AM; Kupfer D
Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
[TBL] [Abstract][Full Text] [Related]
2. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
Dehal SS; Kupfer D
Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation.
Mani C; Gelboin HV; Park SS; Pearce R; Parkinson A; Kupfer D
Drug Metab Dispos; 1993; 21(4):645-56. PubMed ID: 8104124
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
Dehal SS; Kupfer D
Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal SS; Kupfer D
Cancer Res; 1997 Aug; 57(16):3402-6. PubMed ID: 9270005
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.
Mani C; Kupfer D
Cancer Res; 1991 Nov; 51(22):6052-8. PubMed ID: 1933868
[TBL] [Abstract][Full Text] [Related]
7. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen.
Cotreau MM; von Moltke LL; Harmatz JS; Greenblatt DJ
Pharmacology; 2001; 63(4):210-9. PubMed ID: 11729359
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation.
Mani C; Hodgson E; Kupfer D
Drug Metab Dispos; 1993; 21(4):657-61. PubMed ID: 8104125
[TBL] [Abstract][Full Text] [Related]
9. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes P450 and hemoglobin.
Parte P; Kupfer D
Drug Metab Dispos; 2005 Oct; 33(10):1446-52. PubMed ID: 15987777
[TBL] [Abstract][Full Text] [Related]
11. Oxidative metabolism of monensin in rat liver microsomes and interactions with tiamulin and other chemotherapeutic agents: evidence for the involvement of cytochrome P-450 3A subfamily.
Nebbia C; Ceppa L; Dacasto M; Carletti M; Nachtmann C
Drug Metab Dispos; 1999 Sep; 27(9):1039-44. PubMed ID: 10460804
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
13. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
Mahadevan B; Arora V; Schild LJ; Keshava C; Cate ML; Iversen PL; Poirier MC; Weston A; Pereira C; Baird WM
Mol Carcinog; 2006 Feb; 45(2):118-25. PubMed ID: 16329150
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P-450- and flavin-containing monooxygenase-catalyzed formation of the carcinogen N-hydroxy-2-aminofluorene and its covalent binding to nuclear DNA.
Frederick CB; Mays JB; Ziegler DM; Guengerich FP; Kadlubar FF
Cancer Res; 1982 Jul; 42(7):2671-7. PubMed ID: 7083159
[TBL] [Abstract][Full Text] [Related]
17. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
18. The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs.
Chung WG; Buhler DR
Toxicol Appl Pharmacol; 1994 Aug; 127(2):314-9. PubMed ID: 8048076
[TBL] [Abstract][Full Text] [Related]
19. Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.
Tang W; Stearns RA; Kwei GY; Iliff SA; Miller RR; Egan MA; Yu NX; Dean DC; Kumar S; Shou M; Lin JH; Baillie TA
J Pharmacol Exp Ther; 1999 Dec; 291(3):1068-74. PubMed ID: 10565826
[TBL] [Abstract][Full Text] [Related]
20. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
